2020 Guide to Patient Support Services

Sanofi Genzyme

Sanofi Genzyme’s CareASSIST is a support program designed to help eligible patients to access prescribed oncology therapies. Sanofi Genzyme oncology and supportive care drugs, their indications, and support programs are listed in the Table.

CareASSIST provides resources and support, including financial assistance, access and reimbursement, and resource support.

Financial assistance
CareASSIST offers programs and services that can help eligible patients with the cost of prescribed medication.

Access and reimbursement
Care­ASSIST offers assistance in navigating the insurance process, including insurance benefits investigations, coding and billing assistance, claims assistance, and information about prior authorizations and appeals.

Resource support
CareASSIST offers information on independent support services for patients and caregivers, as well as medication ordering and replacement information.


CareASSIST Patient Assistance Program

Patients with no insurance or those who lack insurance coverage can receive their prescribed Sanofi Genzyme medication at no cost through the CareASSIST Patient Assistance Program. To be eligible for assistance through this program, the patient must:

  • Be a resident of the United States or its territories or possessions
  • Be under the care of a US-licensed provider who is authorized to prescribe, dispense, and administer medicines
  • Have no insurance coverage or no coverage for the prescribed therapy
  • Have an annual household income that does not exceed the greater of $100,000 or 500% of the federal poverty level
  • Patients who are enrolled in Medicare Part B and have no supplemental insurance coverage may be eligible for this program.

If a patient does not meet these eligibility criteria and still needs assistance, CareASSIST may be able to help. CareASSIST Patient Access Specialists may be able to identify ­potential alternate coverage sources including Medicaid, state health exchanges, state pharmaceutical assistance programs, and independent charitable foundations. More information on financial eligibility is available online.

CareASSIST Copay Program

Patients who have commercial insurance may qualify for the CareASSIST Copay Program and pay as little as $0 out of pocket, including any drug-specific copay, coinsurance, and insurance deductibles up to $25,000 in assistance annually for select medications. See SanofiCareASSIST.com/hcp for more information. To be eligible for assistance through the CareASSIST Copay Program, the patient must:

  • Be a resident of the United States or its territories or possessions
  • Not be participating in federal- or state-funded insurance programs
  • Must have a valid prescription for an FDA-approved indication.

There is no income requirement to qualify for this program.

CareASSIST Resource Support

CareASSIST Patient Access Specialists can help patients to connect them with additional independent support services such as clinical support services, transportation assistance, health supply and cosmetic aids, home care services support, food and nutritional programs, and patient advocacy support.


To enroll in CareASSIST, the completed enrollment form must be submitted by fax to 855-411-9689, or by mail, to the address provided on the application form. The patient and a licensed healthcare provider who is authorized to prescribe, dispense, and administer medicines in the United States must fill out and sign the application form. For questions about the program and for assistance with enrollment, call 833-930-2273.

The application form for the CareASSIST Patient Assistance Program is available online at SanofiCareASSIST.com/hcp.

All medications supported by Sanofi CareASSIST are shipped directly to the healthcare provider’s office.


Patient support programs

Elitek (rasburicase)
Management of plasma uric acid levels in patients with leukemia, lymphoma, or with solid tumors who are receiving anticancer therapy
Patient support program

Jevtana (cabazitaxel)
Treatment of metastatic castration-resistant prostate cancer, in combination with prednisone, after docetaxel-containing regimen
Patient support program

Libtayo (cemiplimab-rwlc) injection
Treatment of patients with metastatic cutaneous squamous-cell carcinoma or with locally advanced cutaneous squamous-cell carcinoma who are not candidates for curative surgery or radiation
Patient support program

Mozobil (plerixafor)
For autologous transplant in patients with non-Hodgkin lymphoma or multiple myeloma, in combination with granulocyte colony-stimulating factor
Patient support program

Thymoglobulin (antithymocyte globulin)
For prophylaxis and treatment of acute rejection in patients receiving a kidney transplant, with concomitant immunosuppression
Patient support program

Zaltrap (ziv-aflibercept)
Treatment of metastatic colorectal cancer, in combination with 5-fluorouracil, leucovorin, and irinotecan
Patient support program

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: